Rykindo NDA for Schizophrenia, Bipolar Disorder Submitted to FDA - Monthly Prescribing Reference

Rykindo NDA for Schizophrenia, Bipolar Disorder Submitted to FDA  Monthly Prescribing Reference

Luye Pharma Group announced the submission of a New Drug Application (NDA) for Rykindo (risperidone extended-release microsphere; LY03004) for ...